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Background: Many miR genes are located within or around CpG islands. It is unclear whether methylation of these
CpG islands represses miR transcription regularly. The aims of this study are to characterize gastric carcinoma
(GC)-related methylation of miR CpG islands and its relationship with miRNA expression.
Methods: Methylation status of 9 representative miR CpG islands in a panel of cell lines and human gastric samples
(including 13 normal biopsies, 38 gastritis biopsies, 112 pairs of GCs and their surgical margin samples) was
analyzed by bisulfite-DHPLC and sequencing. Mature miRNA levels were determined with quantitative RT-PCR.
Relationships between miR methylation, transcription, GC development, and clinicopathological characteristics were
statistically analyzed.
Results: Methylation frequency of 5 miR CpG islands (miR-9-1, miR-9-3, miR-137, miR-34b, and miR-210) gradually
increased while the proportion of methylated miR-200b gradually decreased during gastric carcinogenesis
(Ps< 0.01). More miR-9-1 methylation was detected in 62%-64% of the GC samples and 4% of the normal or gastritis
samples (18/28 versus 2/48; Odds ratio, 41.4; P< 0.01). miR-210 methylation showed high correlation with H. pylori
infection. miR-375, miR-203, and miR-193b methylation might be host adaptation to the development of GCs.
Methylation of these miR CpG islands was consistently shown to significantly decrease the corresponding miRNA
levels presented in human cell lines. The inverse relationship was also observed for miR-9-1, miR-9-3, miR-137, and
miR-200b in gastric samples. Among 112 GC patients, miR-9-1 methylation was an independent favourable predictor
of overall survival of GC patients in both univariate and multivariate analysis (P< 0.02).
Conclusions: In conclusion, alteration of methylation status of 6 of 9 tested miR CpG islands was characterized in
gastric carcinogenesis. miR-210 methylation correlated with H. pylori infection. miR-9-1 methylation may be a
GC-specific event. Methylation of miR CpG islands may significantly down-regulate their transcription regularly.Background
miRNA are an abundant class of small non-coding RNAs
that mainly regulate gene expression at the post-
transcriptional level. They play critical roles in the renewal
and differentiation of stem cells and help maintain cell
lineages. Previous research has shown that in cancer sev-
eral of the miR genes such as miR-200b/200a/429, miR-21,
miR-30b, miR-30d, miR-31, and miR-423 are upregulated,
while other miR genes such as miR-143 and miR-145 are* Correspondence: dengdajun@bjmu.edu.cn
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reproduction in any medium, provided the ordownregulated [1-3]. Evidence suggests that changes in
miRNA expression occur frequently in many cancers and
these variations either contribute to carcinogenesis or
reflect the development and progression of cancers.
There are a number of pathways that may affect
mature miRNA levels in cells and tissues, such as gene
amplification or deletion, transcriptional upregulation or
downregulation, post-transcriptional processing, and
miRNA degradation [4-7]. It is well known that some
intragenic miR genes, such as miR-218-2, are coordi-
nately transcribed with their host genes through co-
regulation mechanisms [8]. However, many miR genes
are extragenic and a certain proportion of intragenic
miR genes such as miR-9-1 are transcribed in a hostThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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moter region of most miR genes are not characterized,
especially with regard to the extragenic miR genes, the
exact regulatory mechanisms of miR transcription are
far from clear.
Methylation or hypermethylation of CpG islands in the
region of transcription starting sites (TSS) is generally
recognized to repress gene transcription epigenetically.
Unlike protein-coding genes that may span multiple CpG
islands, the miR genes may be shorter than a CpG island,
and in some cases, multiple miR genes (i.e., a miR gene
cluster) may be located within or flanking a single CpG is-
land (Additional file 1: Table S1). Aberrant methylation of
CpG islands associated with miR genes, such as let-7a-3
and miR-34a, is frequently observed in many cancers
[10,11]. It has been suggested that methylation of the CpG
islands that are associated with miR genes (i.e. miR-203,
miR-152, miR-124-1, miR-34b/c, miR-129-2, miR-9-1,
miR-130b, miR-124-2, and miR-181c) might inversely cor-
relate with their expression levels [12-17]. However,
whether or not transcription of miR genes is regularly
affected by the methylation status of miR CpG islands has
not been systemically studied.
It is well known that abnormal methylation or
demethylation of CpG islands in a small proportion
(<1%) of the cell population can be sensitively detected in
cellular heterozygous tissue samples. This demonstrates
the advantage of methylation analysis over alterations of
gene expression at the RNA and protein levels that can
only be detected when such a changes is present in a
large proportion of a cell population in a sample [18].
Our bioinformatic analysis shows 50, 9, and 70 of 721
human miR genes in the miRbase (Release 14.0) are
located, respectively, within, flanking, and near CpG
islands (collectively we will refer to these as miR CpG
islands; Additional file 1: Table S1). We hypothesize that
aberrant methylation of miR CpG islands may occur dur-
ing development and progression of cancers. Therefore
they could be used as candidate genes not only for pre-
diction of cancer prognosis, but also for investigation of
the methylation-expression association in vivo. Thus,
CpG islands of 9 disease-related miR genes, including 5
extragenic miR genes or gene clusters (miR-9-3, miR-137,
miR-200b/200a/429, miR-203, and miR-375) and 4
intragenic genes or gene clusters (miR-9-1, miR-34b/c,
miR-193b/365-1, and miR-210), were selected as the rep-
resentative genes in the present study (Additional file 1:
Table S1). The methylation-expression association for 3 of
these miR genes has not been previously established
(Additional file 1: Table S2) [12,14,19-27]. We initially
screened for gastric carcinoma (GC)- or host-related aber-
rant miR methylation and then investigated the
methylation-expression association in vitro and in vivo.
Associations between clinicopathological features of GCpatients and methylation of these miR CpG islands were
also analyzed.
Methods
Cell line sources and cell culture
Source information of used cell lines used in this study:
RKO cell line, provided by Dr. Guoren Deng at University
of California San Francisco; SW480 and HCT116 were pro-
vided by Dr. Yuanjia Chen at Peking Union Medical Col-
lege Hospital; MKN74 and 293 T provided by Tokyo
Medical and Dental University; PC-3 was purchased from the
Cell Line Bank at the Chinese Academy of Medical Science;
HL60 and KG1A were obtained from the Hematology
Department of Peking University First Hospital; Du145 was
obtained from Hanmi Pharmacy Company; Siha was pro-
vided by Peking University People’s Hospital. HepG2 was
provided by Dr. Qingyun Zhang, Calu3 and A549 by
Dr. Zhiqian Zhang, H1299 and AGS by Dr. Chengchao
Shou, MKN45 by Dr Youyong Lv, and other cell lines
(SGC7901, BGC823, MGC803, HeLa and GES-1) by
Dr. Yang Ke, all at Peking University Cancer Hospital/Insti-
tute. These cell lines were cultured at 37°C in 5% CO2, using
various culture media. MKN45, MKN74, SGC7901,
BGC823, MGC803, HL60, KG1A, A549, H1299, GES-1,
HepG2, 293 T, Du145, and RKO were cultured in 90%
RPMI-1640 and 10% FBS. PC-3 and AGS were cultured in
90%F-12 and 10% FBS. Calu3, HeLa and Siha were cultured
in 90% DMEM and 10% FBS. SW480 and HCT116 were
cultured in 90% DMEM:RPMI-1640 (1:1) and 10% FBS.
Patients and tissue samples
Surgical primary GC samples and their paired non-
cancerous surgical margin (SM) samples were collected
from 112 inpatients (average age 59.2 years [range, 32–79];
80 males and 32 females; 78 non-cardiac GCs and 34 car-
diac GCs; 40 GCs at pTNM stage I~ II and 59 at the stage
III ~ IV) at Peking University Cancer Hospital. Follow-up
data for all patients was collected for at least five years. All
clinical samples, as well as histopathological and followup
information for each case were obtained according to
approved institutional guidelines. Gastric biopsies from 13
healthy subjects and 38 gastritis outpatients collected from
the same hospital were used as non-cancer patient controls.
Before bisulfite modification each patient’s gastric genomic
DNA sample was analyzed for the presence of H. pylori-
specific 23 S rDNA by a PCR assay as described previ-
ously [28]. The Institutional Review Boards of Peking Uni-
versity Cancer Hospital and Institute approved the study
(#2011041207), and all patients gave written informed
consent.
DNA extraction and bisulfite modification
Cancer cell line and tissue sample genomic DNA (1.8 μg)
was isolated using phenol/chloroform extraction [29]. The
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converted to uracil residues (becoming thymidine residues
in PCR products) by the addition of 5 M sodium bisulfite
[30]. The WizardW DNA Clean-Up System Kit (Promega)
was used to purify the bisulfite-treated DNA before PCR
amplification.
PCR amplification and quantification of miR CpG island
methylation by DHPLC
CpG-free universal primer sets were used to amplify miR
CpG islands by hot-start PCR polymerase (Additional file 1:
Figure S1 and Additional file 1: Table S3). Sequences of
CpG islands embedded or flanked these related miR genes
were used to design the primers. The PCR products were
then analyzed quantitatively by DHPLC on the WAVEW
DNA Fragment Analysis System [31]. Elution profiles of
miR-9-3, miR-200b, and miR-203 methylation was analyzed
with an ultraviolet detector; other miR gene methylation
was detected with the post column HSX-3500 Accessory
(Transgenomic, Inc., Omaha, USA) and a high–sensitivity
fluorescence (FL) detector (excitation at 450 nm, emission
at 520 nm) [32]. Methylated and unmethylated miR gene
PCR products were separated by a DNASepW analytical col-
umn (Transgenomic) at the corresponding partial denatur-
ing temperature (Additional file 1: Table S3 and Figure
S2-10). The peak areas corresponding to the methylated
and unmethylated PCR products were used to calculate the
proportion of methylated miR CpG island [the proportion
of methylated copies =methylation-peak area/ total peak
area] as previously described [33]. M.SssI-methylated gen-
omic DNA from blood samples was used as a positive
control.
Bisulfite clone-sequencing
Fresh PCR products of miR CpG islands amplified with the
CpG-free universal primer sets were cloned with the
pGEM-T Easy kit (Promega, Madison, USA) and
sequenced with an Applied Biosystems 3730xl DNA
Analyzer at SinoGeneMox Company (Beijing, China).
Extraction of RNA and detection of mature miRNA level
with quantitative RT-PCR assays
Total 50 ng RNA was extracted from fresh tissue samples
or cell lines using the TRIzol reagent (Life Technologies,
Carlsbad, USA) according to the manufacturer’s protocol.
Corresponding cDNA samples were synthesized using the
TaqManWMicroRNA Reverse Transcription Kit (Life Tech-
nologies) with miR-specific stem-loop inverse transcription
(RT) primers (specific for miR-375 #RT000564, miR-34b
#RT000427, miR-137 #RT000593, and miR-9 #RT000583).
The RT conditions used were 16°C for 30 min ➔ 42°C for
30 min ➔ 85°C for 5 min. The miRNA levels were then
analyzed using a TaqMan Gene Expression Master Mix kit
(Life Technologies) with the corresponding probe andprimers (Life Technologies, miR-375 #TM000564, miR-34b
#TM000427, miR-137 #TM000593, and miR-9 #TM000583).
U6 (Life Technologies, #RT001093 and #TM001093) was
used as the internal reference. The PCR cycling conditions
were 95°C for 10min ➔ followed by 40 cycles of 95°C for
20 sec ➔ 60°C for 1 min. Expression levels of miR-200b
and miR-210 were determined using a standard polyA RT-
PCR assay. Sequences of the RT adaptor primer, the univer-
sal inverse primer and the U6 primer in the regular polyA
RT-PCR assay are shown in Additional file 1: Table S5. RT
conditions were 55°C for 5 min ➔ followed by 25°C for
10 min ➔ 42°C for 1 hr ➔ and 70°C for 5 min. The PCR
cycling conditions were 95°C for10min ➔ followed by 40
cycles of 95°C for 20 sec➔ and 61°C for 1 min.
Statistical analysis
SPSS 16.0 Trend-test and Pearson’s Chi-square test were
used to analyze the miR methylation frequency difference
between normal biopsies, gastritis lesions, GC and SM
samples. Kruskal-Wallis H-test and One-Way ANOVA
were used to analyze the miR methylation proportion dif-
ferences between normal biopsies, gastritis lesions, GC, and
SM samples. Fisher’s exact test, Pearson’s Chi-square test,
and Trend-test were used to analyze the association
between miR methylation positive rates and the clinico-
pathological features. The Mann–Whitney U-test and Stu-
dent’s t-test were used to analyze the association between
the proportion of methylated miR alleles and the clinico-
pathological features. Kaplan-Meier and Cox-Proportional
Hazards methods were used for univariate and multivariate
analysis to compare overall survival of GC patients with dif-
ferences in methylation status of miR CpG islands. All stat-
istical tests were two-sided, and P<0.05 was considered
statistically significant.
Results
Characterization of methylation or demethylation of 6
miR CpG islands related to the development of GCs
We amplified bisulfite-treated templates of 9 representa-
tive miR CpG islands with CpG-free primers and devel-
oped 9 DHPLC assays to analyze the methylation status
of the CpG islands in PCR products of 4 intragenic miR
genes (miR-9-1, miR-34b, miR-193b, miR-210) and 5
extragenic miR genes (miR-9-3, miR-137, miR-200b, miR-
203 and miR-375), respectively (Figure 1, Additional file 1:
Table S3, and Additional file 1: Figure S1–S10). These
DHPLC assays revealed that the methylation positive rate
of 5 miR CpG islands (miR-9-1, miR-9-3, miR-34b, miR-
137, and miR-210) was significantly increased concur-
rently with the severity of pathological changes in the
stomach. These findings strongly suggest that methylation
of these miR CpG islands is related to the development of
GCs (trend-test, miR-9-1, P< 0.001; miR-9-3, P< 0.001;
miR-34b, P= 0.008; miR-137, P< 0.001; miR-210,
Figure 1 DHPLC chromatograms and bisulfite sequencing of 7 miR CpG islands in representative cell lines and gastric tissue samples.
Both human peripheral blood DNA (BLOOD) and its M.SssI-methylated products (M.BLOOD) were used as controls. All CpG sites in the amplicon
of each miR CpG island are also listed above the results of bisulfite sequencing. Each row represents one clone; each pink bar represents a
methylated CpG site. The corresponding chromatogram of each sequenced sample (right column) is shown (left column).
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18 of 28 GCs (sensitivity, 64%), but only in 2 of 48 normal
or gastritis biopsies showed methylation (specificity, 96%).
Although methylation of miR-200b was detected in almost
all gastric tissues samples, the proportion of methylated
miR-200b in normal or gastritis tissues (46%~100%) was
significantly higher than that in both SM and GC samples
(41%~47%) (Mann–Whitney U-test, gastritis biopsies ver-
sus SMs, P= 0.001; Table 1). This suggests that miR-200b
demethylation was a GC, patient-specific event. Bisulfite
sequencing of these miR CpG islands confirmed the data
obtained from DHPLC analysis (Figure 1).
Except for miR-9-1 and miR-137, the methylation
positive rates or proportions of methylated miR-9-3,
miR-34b, miR-210, and miR-200b in GCs were similar to
those in SMs (Table 1). To validate if methylation of
some of these miR genes is a field-effect happens simul-
taneously in both cancerous and non-cancerous tissues
in the stomach due to the same exposure to environ-
mental factors, we detected the methylation data inanother subset of GC and SM samples from 84 patients
and found that the positive rate and proportion of
methylated miR-9-1 in GCs was still significantly higher
than that in SMs (60.7% versus 32.1%; Pearson’s Chi-
square test, P= 0.001; Sign rank test, P < 0.001;
Additional file 1: Table S4, Subset-2). The average pro-
portion of the methylated miR-137 was also significantly
higher in GCs than SMs (Mean ± SD, 26 ± 2 versus
38 ± 2, Paired t-test, P< 0.001). As expected a significant
difference in the positive rate or the proportion of
methylated miR-9-3, miR-34b, miR-210, and miR-200b
was not observed between GC and SM samples. These
results confirmed that miR-9-1 and miR-137 methylation
was a tumor-specific event and that miR-9-3, miR-34b,
and miR-210 methylation, as well as miR-200b demethy-
lation, was a field-effect that occurred during gastric
carcinogenesis.
Furthermore, the positive rate of methylated miR-203
and miR-375 gradually increased from normal to gastritis
to SM samples, but significantly decreased in GCs
Table 1 Methylation status of miR CpG islands in gastric mucosa samples with different pathological changes in GC














Mean ± SD t/F/χ2-value P-value
miR-9-1 Normal 1/13 (7.7) 27.598 <0.001 a NA NA
Gastritis 1/35 (2.9) NA
SM 9/28 (32.1) 17 [13–30] 20 ± 4 t=−3.039 0.005 g
GC 18/28 (64.3) 29 [19–40] 32 ± 4
miR-9-3 Normal 6/13 (46.2) 23.389 <0.001 a 38 [31–59] 43 ± 6 F= 1.639 0.189 h
Gastritis 15/37 (40.5) 43 [36–48] 42 ± 2
SM 26/28 (92.9) 38 [26–44] 36 ± 2
GC 26/28 (92.9) 37 [26–43] 36 ± 2
miR-137 Normal 5/13 (38.5) 18.626 <0.001 a 10 [4–41] χ2= 8.065 0.045 d
Gastritis 24/38 (63.2) 19 [7–36]
SM 25/26 (96.4) 15 [7–40] 21 ± 3g
GC 24/26 (92.3) 36 [20–51] 37 ± 4
miR-34b Normal 6/13 (46.2) 6.947 0.008 a 13 [7–19] χ2= 0.658 0.883 d
Gastritis 13/36 (36.1) 11 [3–20]
SM 22/28 (78.6) 11 [4–18]
GC 19/28 (67.9) 10 [5–32]
miR-200b Normal 13/13 (100) 0.486 0.922 f 54 [52–83] χ2= 17.883 <0.001 d
Gastritis 35/36 (97.2) 52 [46–100] e
SM 27/28 (96.4) 44 [40–47]
GC 27/28 (96.4) 48 [40–53]
miR-210 Normal 2/13 (15.4) 11.908 0.001 a NA NA
Gastritis 13/38 (34.2) 7 [5–10]
SM 22/27 (81.5) 11 [5–22]
GC 16/27 (59.3) 9 [4–16]
miR-193b Normal 0/13 7.045 0.008 b NA NA
Gastritis 2/37 (5.4) NA
SM 7/28 (25.0) 5 [4–14]
GC 4/28 (14.3) 5 [2–12]
miR-203 Normal 5/13 (38.5) 5.617 0.018 b 32 [29–75] χ2= 2.957 0.398 d
Gastritis 20/38 (52.6) 31 [26–36]
SM 21/28 (75.0) 34 [30–36]
GC 11/28 (39.3)c 32 [29–35]
miR-375 Normal 0/13 12.266 <0.001 b NA NA
Gastritis 13/38 (34.2) 3 [3–4] e
SM 16/28 (57.1) 7 [4–14]
GC 8/28 (28.6) c 17 [8–21]
a, Trend test, among Normal, Gastritis, SM and GC samples; b, Trend-test, among Normal, Gastritis, and SM samples; c, Pearson’s Chi-square test, GC versus SM:
miR-203, χ2= 7.292, P = 0.007; miR-375, χ2= 4.667, P = 0.031; d, Kruskal-Wallis H-test; e, Mann–Whitney U-test: Gastritis versus SM, miR-200b,U= 230.000, P = 0.001;
Gastritis versus GC, miR-375, U= 46.000, P = 0.011; SM versus GC, miR-137, U= 170.000, P= 0.009; f, Pearson’s Chi-square test, among Normal, Gastritis, SM and GC
samples; g. Paired t-test: SM versus GC, miR-137, t=−2.652, P = 0.014; h. One-way ANOVA; NA, not available.
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P=0.007;miR-375, P=0.031; Table 1). In the Subset-2 sam-
ples, we also analyzed miR-375 methylation and found
more miR-375 methylation in SMs than in GCs again
(Pearson Chi-square test, P= 0.034; Additional file 1:
Table S4). These data imply that miR-375 (and miR-203)
methylation is not GC-specific and might be one kind of
host adaptation in the non-malignant tissues to the de-
velopment of GCs.miR methylation and H. Pylori infection
To determine if H. pylori infection plays a role in miR
methylation, we looked for H. pylori-specific 23 S rDNA
in gastric genomic DNA samples by PCR and found that
the H. pylori-positive rate increased concurrently with
the severity of pathological changes [15.4% (2 of 13) of
normal gastric biopsies, 52.6% (20 of 38) of gastritis
lesions, and 69.0% (29 of 42) SM biopsies; trend-test,Figure 2 Comparison of miR methylation in various gastric mucosa sa
gastritis biopsies from control outpatients without malignant disease; (B an
carcinoma, respectively; H. pylori-specific 23 S rDNA was detected by PCR.P= 0.001] and decreased in GC samples (18 of 42= 42.9%;
GCs versus SMs, Pearson Chi-square test, P= 0.016;
Additional file 1: Figure S11). H. pylori-positive gastritis/
normal and SM samples showed significantly higher
methylation of miR-210 methylation than H. pylori-nega-
tive samples (P=0.036 and 0.022, respectively; Figure 2A
and B).Inversed relationship between miR methylation of CpG
islands and their corresponding expression levels
To investigate the relationship between the above aber-
rant miR methylation and the transcription of the corre-
sponding miR gene, we quantified the mature miRNA
levels of miR-9-1, miR-9-3, miR-34b, miR-137, miR-210,
miR-200b, (and miR-375), whose methylation status is
related to the development of GC (and GC host adapta-
tion) as described above, in a set of human cell lines
with different methylation status of miR CpG islands.mples with and without existence of H. pylori. (A) Normal or
d C) Surgical margin and tumor samples from patients with gastric
Figure 3 The relationship between expression level and
methylation status of miR genes in human cell lines and gastric
tissue samples. (A-G) The correlation analysis between methylation
proportion of miRNA CpG islands and their mature miRNA
expression levels in the target CpG island methylated and
unmethylated human cell lines; (H-P) Expression of miRNAs in 20
paired, fresh gastric carcinoma samples; (U) Target CpG island
unmethylated cell lines; (M) Target CpG island methylated cell lines;
(U/M) Target CpG island partially methylated cell lines.
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cell lines was determined by DHPLC as illustrated in
Additional file 1: Figure S2–S10. Results of quantitative
RT-PCR assays showed that in the tested cell lines con-
taining methylated miR alleles the mature miRNA levels
of all 6 GC-related miR genes and one host adaptation
miR gene were significantly lower than those detected in
the cell lines containing unmethylated miR alleles
(Figure 3A-G).
We further analyzed the miRNA levels of 20 pairs of
fresh GC and SM samples and found a significantly
higher expression level of miRNA-200b, miRNA-375,
and miRNA-210 in SMs than in GCs (Paired t-test:
Ps≤0.030; Additional file 1: Figure S12). The miRNA-137
levels in SMs were also higher than those in GCs, but
was not statistically significant (P= 0.059). The expres-
sion levels of miRNA-9 and miRNA-34b were similar
between SMs and GCs. Most importantly, an inverse
relationship between miR methylation and the corre-
sponding expression level was observed for miR-9-1,
miR-9-3, miR-137, and miR-200b in these gastric tissue
samples (Spearman’s Rank Correlation analysis, miR-9-1,
rs=−0.533, P= 0.001; miR-9-3, rs=−0.464, P= 0.004;
miR-137, rs=−0.378, P= 0.019; miR-200b, rs=−0.409,
P= 0.010; Figure 3H-K). A weak inverse methylation-
expression relationship was also found for miR-375 in
these tissue samples (rs =0.287, P= 0.085; Figure 3O).
Such a relationship was not observed for miR-34b and
miR-210 (Figure 3L, N).
miR methylation correlated to clinicopathological
characteristics of GC patients
To study the possibility of using miR methylation as
a prognosis predictor of GCs, we determined the preva-
lence of methylation of 7 miR genes and analyzed the
relationship between the clinicopathological features of
GC and the corresponding methylation levels of these
miR CpG islands studied above for all 112 GC patients
(Table 2 and Additional file 1: Table S6). Higher miR-9-1
methylation was consistently observed in well/moderately
differentiated, non-metastatic/less-invasive GCs, but this
was not statistically significant. The proportion of demethy-
lated miR-200b was higher in lymph metastatic GCs than
in non-metastatic GCs (median, 45% versus 53%; Mann-
Table 2 Comparison of methylation of 7 miR CpG islands in 112 GC samples from patients with various clinicopathological characteristics
Clinicopathological
features




































Age ≤60 (n= 49) 46.9 a 21 [14–38] 68.8 35 [31–42] 95.9 34 [16–48] b 62.5 5 [2–16] 92.9 49 [43–55] 54.3 3 [2–14] 65.1 9 [5–27]
>60 (n= 63) 73.0 33 [18–44] 61.0 36 [30–44] 93.3 47 [29–61] 54.2 10 [3–23] 87.7 48 [40–56] 38.3 3 [2–14] 72.9 10 [5–17]
Sex Male (n= 80) 61.2 31 [14–45] 62.7 35 [30–42] 96.1 40 [24–54] 53.8 7 [3–18] 88.4 48 [40–56] 44.6 3 [2–7] 69.9 9 [5–17]
Female
(n= 32)
62.5 27 [17–36] 68.8 41 [30–43] 90.6 43 [18–54] 69.0 8 [2–26] 93.3 51 [46–55] 46.9 8 [2–19] 69.0 12 [5–22]
Preoperative
chemotherapy
No (n= 100) 63.0 32 [16–44] 63.2 35 [30–43] 93.8 39 [23–56] 58.9 7 [3–18] 91.0 49 [41–56] 44.7 4 [2–16] 69.6 9 [5–19]
Yes (n= 9) 55.6 21 [12–31] 66.7 37 [31–54] 100 49 [30–53] 44.4 5 [2–16] 71.4 49 [42–76] 44.4 2 [2–4] 57.1 13 [10–24]
Location Cardiac
(n= 34)
64.7 37 [21–47] 65.6 43 [35–51] b 90.9 49 [28–61] b 57.6 8 [3–23] 75.0 d 43 [38–52] 31.2 3 [1–8] 64.5 9 [4–17]
Non-cardiac
(n= 78)
60.3 28 [14–42] 64.0 34 [30–42] 96.1 38 [20–52] 58.1 6 [3–18] 97.0 50 [42–56] 51.4 3 [2–16] 71.8 10 [5–21]
Differentiation Well/Mod.
(n= 29)
72.4 a 27 [9–44] 69.0 37 [30–50] 86.2 45 [31–53] 44.4 9 [3–16] 84.6 53 [42–58] 40.7 3 [2–4] 73.1 9 [4–17]
Poor (n= 78) 56.4 31 [19–42] 63.0 35 [30–42] 97.3 38 [22–55] 64.0 6 [3–19] 91.3 48 [40–54] 45.9 3 [2–14] 66.2 10 [5–21]
Vascular
embolus
No (n= 60) 65.0 26 [14–45] 70.2 35 [31–43] 89.7 d 45 [26–59] 55.0 10 [3–19] c 92.5 50 [42–57] 51.7 3 [2–13] 70.2 9 [5–20]
Yes (n= 49) 59.2 31 [19–39] 55.3 37 [30–43] 100 39 [22–50] 65.9 3 [2–11] 86.0 48 [40–53] 40.0 5 [2–20] 66.7 11 [5–20]
pTNM stage I-II (n= 40) 70.0 30 [14–47] 67.6 37 [33–45] 89.7 d 46 [35–59] 59.0 10 [3–28] c 91.9 49 [41–56] 51.3 3 [2–8] 64.1 9 [5–19]
III-IV (n= 59) 59.3 30 [19–40] 60.3 39 [32–43] 100 40 [22–53] 58.2 4 [2–17] 87.8 49 [41–54] 41.8 5 [2–20] 70.0 12 [5–28]
Depth of
invasion
T1-2 (n= 25) 68.0 34 [11–52] 72.7 36 [31–44] 84.0
e 48 [36–59] 73.9 10 [3–21] 86.4 52 [44–56] 47.8 2 [2–4] 70.8 9 [3–19]
T3 (n= 53) 62.3 28 [17–41] 58.5 35 [30–43] 96.1 43 [28–53] 49.0 7 [2–24] 91.3 46 [36–56] 48.0 5 [2–18] 68.8 10 [5–18]
T4 (n= 25) 60.0 30 [16–38] 62.5 42 [33–44] 100 31 [15–53] 66.7 5 [2–17] 90.9 49 [41–55] 36.0 8 [3–20] 66.7 14 [5–32]
Lymph node
metastasis
N0 (n= 57) 68.4 26 [13–47] 67.3 35 [32–43] 89.1
d 45 [22–58] 61.8 10 [3–20] 90.6 53 [43–57] c 46.4 2 [2–10] 67.3 9 [5–19]
N1-3 (n= 51) 56.9 31 [21–41] 58.3 39 [30–44] 100 39 [26–52] 58.3 4 [2–16] 88.1 45 [37–52] 47.8 5 [2–20] 69.8 11 [5–23]
Distant
metastasis
M0 (n= 77) 67.5
a 30 [14–44] 64.4 37 [32–43] 92.0 42 [24–56] 60.0 8 [3–19] 91.5 49 [41–56] 46.7 3 [2–13] 68.1 9 [5–17] c
M1 (n= 31) 51.6 30 [21–40] 60.0 36 [30–43] 100 43 [24–53] 60.7 6 [2–17] 83.3 49 [40–53] 48.1 6 [3–20] 69.2 15 [9–28]
* %; [25-75%], 25%-75% percentiles; a, Pearson’s Chi-square test, miR-9-1 for age, differentiation, distant metastasis: χ2= 7.924, 2.271, 2.402, and P = 0.005, 0.132, 0.121, respectively; b, Student t-test: miR-9-3 for location
[42 ± 2 (Mean ± SD) vs 34 ± 1], t= 3.303, P = 0.002; miR-137 for age [34 ± 3 vs 44 ± 3], t=−2.651, P = 0.009; for location [46 ± 3 vs 37 ± 2], t= 2.103, P =0.038; c, Mann–Whitney U-test: miR-34b for pTNM stage/ vascular
embolus, U= 239.000/320.000, P = 0.028/0.025, miR-200b for lymph node metastasis, U= 627.000, P = 0.021; miR-210 for distant metastasis, U= 301.000, P = 0.048; d, Fisher’s exact test: miR-137 for vascular embolus/
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http://www.biomedcentral.com/1471-2407/12/249Whiney U-test, P= 0.021). In contrast, the positive rate
of miR-137 methylation positively correlated with the
depth of invasion, pTNM, lymph metastasis, and vessel
embolus of GCs (trend-test for depth of invasion, P=0.012;
Pearson’s Chi-square test for pTNM/ lymph metastasis/
vascular embolus, P=0.024/ 0.028/ 0.031). Similarly, higher
miR-210 methylation was observed in GCs with distant
metastasis than in GCs without distant metastasis
(P= 0.048). In addition, the positive rate of miR-9-1 methy-
lation and the proportion of methylated miR-137 in elderly
GC patients were significantly higher than in younger
patients (Pearson’s Chi-square test, miR-9-1, P=0.005;
Student’s t-test, miR-137, P=0.009).
Kaplan-Meier analysis showed that the overall survival
of GC patients with miR-9-1 methylation was significantly
longer than in those without methylation (P= 0.017;Figure 4 Overall survival curves of GC patients with different methyla
(A) miR-9-1 methylation used as the classifier; (B) miR-34b methylation used
(D) miR-200b demethylation used as the classifier.Figure 4A). Similarly, the overall survival of GC patients
with high miR-34b methylation (the proportion of methy-
lated miR-34b>4%) was likely longer than those with low
miR-34b methylation (P=0.119; Figure 4B). In contrast, the
overall survival of GC patients with miR-137 methylation
was shorter than for those without methylation, but was
not statistically significant (P= 0.181; Figure 4C). Interest-
ingly, the overall survival of GC patients with high levels
of demethylated miR-200b (proportion of methylated
miR-200b <45%) was shorter than for low demethylation
patients (P= 0.093; Figure 4D). In addition to miR-9-1
methylation, vessel embolus, pTNM stages, invasion, node
and distant metastasis are also significant survival predic-
tors in univariate analysis (Additional file 1: Table S7).
After adjustment for age, sex, differentiation, location, pre-
operative chemotherapy, pTNM stage, and vasculartion status of 4 miR CpG islands in Kaplan-Meier analysis.
as the classifier; (C) miR-137 methylation used as the classifier;
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nostic indicator in multivariate analysis (adjusted P=
0.014; hazard ratios = 0.475 [95% CI, 0.262–0.860]).
Discussion
The expression patterns exhibited by the miR genes reflect
cell lineages and differentiation status of tumor tissue [34].
Increasing attention is currently being focused on miRNAs
due to their contribution to maintaining the pluripotency
of cancer stem/initiating cells and their application poten-
tial as molecular therapy targets and biomarkers. However,
the regulatory mechanisms of miR expression in cells and
alterations of miRNA levels in tumors are far from clear.
In the present study, we characterized the methylation sta-
tus of 9 representative miR CpG islands in human gastric
tissues with various pathological changes and found that
abnormal methylation of 5 miR CpG islands (miR-9-1,
miR-9-3, miR-34b/c, miR-137, and miR-210) and demethy-
lation of miR-200b CpG island correlated with the develop-
ment of GC. Furthermore, methylation of the miR-203 and
miR-375 CpG islands might be one kind of host adapta-
tions to gastric carcinogenesis. Most importantly, we found
that methylation of all these CpG islands was inversely cor-
related with the expression of these miR genes in a panel
of cultured cell lines. To the best of our knowledge, this is
the first comprehensive study to illustrate the inverse rela-
tionship between the methylation of miR CpG islands and
their expression.
Transcription of protein-coding genes is mainly regu-
lated by transcription factors and the accessibility of their
binding sites in the promoter regions. It is well known that
methylation of CpG islands around the TSS can block
transcription factor binding by decreasing the accessibility
of these sites, thus inactivate gene expression epigeneti-
cally. Bioinformatic analysis shows that 129 of 721 (18%)
of the human miR genes in the miRBase (Release 14.0) are
CpG island-related (Additional file 1: Table S1). Of the
CpG related miR genes, 50 locate within CpG islands and
9 closely flank CpG islands with a <600-bp CpG-sporadic
interval; an additional 70 miR genes are near CpG islands
with a 0.6 ~ 10-kb CpG-sporadic interval. It has been sug-
gested that methylation of some miR CpG islands might
be inversely correlated to their expression [12-17]. How-
ever, a solid relationship between miR methylation and
expression has not been thoroughly established as only
weak supporting evidence has been provided in many of
the previous studies, as we have summarized for 9 tested
miR genes/clusters (extragenic miR-9-3, miR-137, miR-
200b/200a/429, miR-203, miR-375; intragenic miR-9-1,
miR-34b/c, miR-193b/365-1, and miR-210) in this present
study (Additional file 1: Table S2) [19-27]. One frequently
used evidence is that methylated miR genes could be
reactivated by inhibitors of DNA methyltransferase(5-aza-cytosine or 5-aza-deoxycytosine) because these
cytosine analogues, which cannot be methylated in DNA,
inhibit maintenance methylation through direct replace-
ment of methylation targets (cytosine residues). However,
this method is not adequate as methyltransferases inhib-
ition that may indirectly reactivate transcription of both
CpG island-free genes and methylated genes through
DNA damage and repair pathways [35].
To investigate systemically if methylation of miR CpG
islands represses transcription of miR genes, various cell
lines and tissue samples with different methylation status
of representative miR CpG islands must be used. Thus,
instead of randomly selecting candidates from the 129
miR CpG islands, we first screened a set of CpG islands
of miR genes that may be abnormally methylated during
gastric carcinogenesis. Initially the methylation status of
9 miR CpG islands in human gastric tissues with various
pathological changes was analyzed with DHPLC. As is
consistent with others’ reports [14,15,19,25,27,36-40],
miR-9-1, miR-9-3, miR-34b, miR-137, and miR-375
methylation was observed in gastric carcinogenesis in the
present study. We also observed methylation changes in
miR-200b, miR-193b, miR-203, and miR-210 CpG islands
in the development of GCs that has not been previously
reported. Interestingly, we found that the proportion of
demethylated miR-200b gradually increased significantly
in gastric tissues along with the severity of these changes.
This suggests that miR-200b demethylation (or hypo-
methylation) may be involved in gastric carcinogenesis.
In addition, miR-203 and miR-375 methylation increased
gradually in gastritis and SM samples, but decreased in
GC samples. This implies that miR-203 and miR-375
methylation is not a GC-specific event, but rather a host
adaptation to gastric carcinogenesis.
Expression of some intragenic miR genes is coordi-
nately regulated by the transcriptional mechanism of
their host genes. However, a certain proportion of intra-
genic miR genes has their own TSS and transcribe in a
host gene-independent pattern [9,41-43]. Unfortunately,
the TSS sites have not been characterized for most
extragenic/intergenic miR genes. It is reported that
expression levels of some miR genes (including intra-
genic miR-152 and miR-34a/b/c and extragenic miR-203,
miR-124-1/124-2, miR-129-2, and miR-181c) inversely
correlate with methylation of their corresponding CpG
islands [11,13,14,16,27,38,44]. In the present study, we
found that methylation or demethylation of all 7 tested
miR CpG islands (GC-related miR-9-1, miR-34b, miR-9-3,
miR-137, miR-210, miR-200b and host-related miR-375)
was consistently, inversely correlated to a statistically sig-
nificant level with their corresponding miRNA levels in a
number of human cell lines in vitro. Such an inverse rela-
tionships could also be observed for the miR-9-1, miR-9-3,
miR-137, and miR-200b CpG islands in gastric tissue
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1 is host gene-independent [9], we cannot exclude the pos-
sibility that the expression of miR-34b and miR-210 genes
may also be coordinately controlled by regulatory mechan-
isms of their host genes. An unbiased correlation study
using a customized, oligo microarray to detect methylation
of all miR CpG islands and expression of intragenic miR
genes and their host genes in various cell lineages at differ-
ent differentiation stages may be useful to clarify which
miR genes may be expressed in a host-gene dependent way.
Taken together, these data strongly suggest that the methy-
lation status of miR CpG islands could play a crucial role in
the regulation of the expression of the related miR genes.
Generally, transcriptional inactivation of a miR gene by
methylation in a few cells should not lead to a visible
decrease in the miRNA level in a tissue sample because
the majority of cells will still exhibit normal miRNA ex-
pression. This help explain why a significant inverse
methylation-expression relationship was not observed for
miRNA-34b, miRNA-210, or miRNA-375 as the average
proportion of methylated miR-34b, miR-210, or miR-375
in SM and GC samples was relatively low (2%~15%).
Hypermethylation of genes in some cell populations and
the concomitant over-expression of these genes in other
cell populations are often reported in the same tissue sam-
ples with chronic inflammation [18]. Therefore, both the
prevalence of miR methylation and the total mature
miRNA levels may be useful predictors for miR inactiva-
tion and expression in tissue samples, especially in the
case of low proportion of methylated miR. Although other
factors certainly affect the miRNA expression levels in
cells, the inverse relationship consistently observed in this
present study between miR methylation and mature
miRNA expression level in a number of monoclonal cell
lines suggests that the cellular heterozygosity may account
for the inconsistent methylation-expression relationship of
some miR in tissue samples.
The miR-9-1, miR-9-2, and miR-9-3 genes all encode
the same mature miRNA-9 that affects cell migration
and proliferation in a tumor type-specific pattern
through the NF-κB1-Snail-E-cadherin [45,46]. Abnormal
miR-9-1 and miR-9-3 methylation is frequently reported
in many cancers including GCs [15,19,40]. In the present
study, we found that the positive rate of miR-9-1 and
miR-9-3 methylation for all 112 GCs was significantly
higher than that in 50 non-malignant tissues collected
from 37 gastritis patients and 13 healthy controls. In all
the tested samples, the prevalence of miR-9-3 methyla-
tion is significantly higher than that of miR-9-1. It has
been reported that miR-9-3 methylation correlates with
poor clinical outcomes for GC patients [40]. However,
our study failed to make the same correlation. In con-
trast, a significant higher of the positive rate and propor-
tion of methylated miR-9-1, but not methylated miR-9-3,was observed in GCs than SMs. This data indicates that
miR-9-1 methylation may be a late cancer-specific event,
while miR-9-3 methylation may be an early field effect
during gastric carcinogenesis. Using miR-9-1 methyla-
tion as a biomarker for GC detection, we found a sensi-
tivity and specificity 62% (69 of 112) and 96% (46 of 48)
could be achieved, respectively. Because the positive rate
of miR-9-1 methylation in GCs or SMs from stage I ~ II
GC patients was similar to that of stage III ~ IV GC
patients (GCs: 70% versus 59%; SMs: 40% versus 25%), it
would be clinically beneficial to determine if miR-9-1
methylation in gastric juice or peripheral blood plasma
could be used as a biomarker for prediction of malignant
transformation of precancerous lesions of the stomach
and early diagnosis of GCs. Although miR-9-1 methyla-
tion does not significantly correlate with differentiation,
local invasion, metastasis, and pTNM stages in the
screening cohort, it does significantly correlate with a
longer overall survival of GC patients in univariate and
multivariate analysis. Combination with the methylation
status of other miR genes failed to strengthen the predic-
tion power of miR-9-1 methylation on the survival of
these patients. Therefore, miR-9-1 methylation might be
an independent predictor of survival.
miR-137 has been reported to target the CtBP1, a co-
repressor of various tumor suppressor genes [47]. Many
studies have reported miR-137 methylation in head and
neck and colorectal carcinomas [22,23,48,49]. We found
that miR-137 methylation was also very common among
gastritis lesion, SM, and GC samples (63%~96%), and the
positive rate of miR-137 methylation increased gradually
in gastric tissues along with the severity of pathological
changes. Therefore, miR-137 methylation may be another
early epigenetic event that occurs during gastric carcino-
genesis. Because the proportion of methylated miR-137
showed a positive correlation with the invasiveness of
GCs, miR-137 methylation may also affect the progression
of the tumor. When compared to the GC patients without
miR-137 methylation, GC patients with miR-137 methyla-
tion were more likely to have a poor overall survival; how-
ever, this effect was not statistically significant. This is
consistent previous study that has reported that miR-137
methylation (by MSP) correlated to the overall survival of
67 patients with head and neck carcinomas [49].
miR-34b and miR-34c constitute a miR gene cluster.
Previous studies have suggested that mature miRNA-34b
and miRNA-34c are targets of P53 [50]. As a tumor sup-
pressor gene, miR-34b/c methylation has also frequently
been reported in many carcinomas including GCs
[14,51,52]. miR-34b methylation has been reported to re-
late to the invasiveness of non-small lung carcinoma,
colorectal carcinoma, GC, and melanoma [53-55]. In the
present study, we did not find a significant correlation
between miR-34b methylation and GC invasion;
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was observed in stage I ~ II GCs than in stage III ~ IV
GCs (P= 0.025). The overall survival of GC patients with
methylated miR-34b (the proportion > 4%) was likely to
be longer than in those patients without the methylation.
In addition, we found that the prevalence of miR-34b
methylation between SM and GC samples was similar;
this is consistent with a recent report that miR-34b
methylation might be an early field-effect in the develop-
ment of GCs [55].
The miR-200b gene is located in the miR-200b/miR-
200a/miR-429 cluster. Its function is related to the pro-
cesses of epithelium-mesenchymal transition (EMT) by tar-
geting ZEB1 and ZEB2 and results in E-cadherin silencing
[56-58]. There is a CpG island upstream of this cluster
which contains a 4-kb CpG-sporadic interval. It has been
reported that miR-200a/b is hypomethylated and over-
expressed in pancreatic cancers and that circulating
miRNA-200 may be used as a cancer biomarker. The posi-
tive relationship between miR-200b demethylation and
over-expression has also been previously found [59]. In the
present study, we observed that full demethylation of the
miR-200b CpG island was a common field event in both
GC and SM samples. Because the proportion of demethy-
lated miR-200b in gastritis/normal biopsies was signifi-
cantly lower than that in SM and GC samples, miR-200b
demethylation might be another potential GC biomarker.
miR-210 is a hypoxia inducible gene which may inhibit
cancer cell survival and proliferation through targeting
FGFRL1 [60]. It has been reported that miR-210 may dir-
ectly bind to vacuole membrane protein 1 (VMP1) and
promote cancer metastasis [61]. miR-210 methylation has
been previously reported to be presented in glioma [62].
We found that miR-210 methylation not only correlated
with the severity of gastric pathogenesis, but also corre-
lated with H. pylori infection. According to the possible
cause effect relationship between H. pylori infection and
the development of GCs, miR-210 inactivation by DNA
methylation may play a role in gastric carcinogenesis.
miR-375 promotes cancer cell proliferation through
RASD1-ERα pathway [63]. methylation has been previ-
ously reported in melonoma [64], breast cancer [63],
gastric carcinoma [39] and hepatocellular carcinoma
[12]. However, our present study found that for the 106
patients studied, there was a significant higher positive
rate and proportion of methylated miR-375 present in
SMs compared to GCs. Because significant correlation
between miR-375 methylation and H. pylori infection
was not observed among the tested gastric samples, we
suggest that miR-375 methylation might be a unique
host adaptation to the development of GCs.
Previous studies have shown that miR-203 methylation
drives H. pylori-associated gastric lymphomagenesis
[65]. miR-203 and miR-193b methylation has also beenreported in hepatomas and prostate cancer, respectively
[12,37]. We observed that the positive rate of miR-203
and miR-193b methylation increased in normal, gastritis,
and SM tissues, but decreased in GCs as did miR-375
methylation pattern. However, correlation between
H. pylori infection and miR-203 and miR-193b methyla-
tion was not found in any of the gastric tissue samples that
were studied. Therefore, we hypothesize that miR-203 and
miR-193b methylation may also be a host adaptation to
the development of gastritis or GCs.
Conclusions
In conclusion, alteration of methylation status of 6 of 9
tested miR CpG islands was characterized in gastric car-
cinogenesis. miR-210methylation correlated with H. pylori
infection. miR-9-1 and miR-137 methylation may be a
GC-specific event. Methylation of miR CpG islands may
significantly down-regulate their transcription regularly.
Additional file
Additional file 1: Figure S1. Illustrations of 9 tested miR-hosting CpG
islands. Open frame, location of pre-miRNA transcript. Open arrow, pre-
miRNA transcript direction; Blue-underline, locations of the forward and
reversed primer-matching regions used to detect methylation of CpG
island with DHPLC and bisulfite sequencing; Purple vertical bars, CpG
sites. Figure S2. DHPLC chromatogram of methylated and unmethylated
miR-9-1 in various cell lines. UV-detector; the partial denaturing
temperature, 55.4°C; U, peak for the unmethylated PCR products; M, peak
for the methylated PCR products; B, peripheral blood DNA; MB, M.sssI-
methylated blood DNA. Figure S3. DHPLC chromatogram of methylated
and unmethylated miR-9-3 in various cell lines. UV-detector; the partial
denaturing temperature, 58.5°C; U, peak for the unmethylated PCR
products; M, peak for the methylated PCR products; B, peripheral blood
DNA; MB, M.sssI-methylated blood DNA. Figure S4. DHPLC chromatogram
of methylated and unmethylated miR-34b in various cell lines. UV-
detector; the partial denaturing temperature, 56.8°C; U, peak for the
unmethylated PCR products; M (partial or full), peak for the partially or
fully methylated PCR products; B, peripheral blood DNA; MB, M.sssI-
methylated blood DNA. Figure S5. DHPLC chromatogram of methylated
and unmethylated miR-210 in various cell lines. Fluorescence-detector; the
partial denaturing temperature, 58.7°C; U, peak for the unmethylated PCR
products; M, peak for the methylated PCR products; B, peripheral blood
DNA; MB, M.sssI-methylated blood DNA. Figure S6. DHPLC
chromatogram of methylated and unmethylated miR-137 in various cell
lines. Fluorescence-detector; the partial denaturing temperature, 58.3°C; U,
peak for the unmethylated PCR products; M, peak for the methylated PCR
products; B, peripheral blood DNA; MB, M.sssI-methylated blood DNA.
Figure S7. DHPLC chromatogram of methylated and unmethylated
miR-375 in various cell lines. UV-detector; the partial denaturing
temperature, 55.7°C; U, peak for the unmethylated PCR products; M, peak
for the methylated PCR products; B, peripheral blood DNA; MB, M.sssI-
methylated blood DNA. Figure S8. DHPLC chromatogram of methylated
and unmethylated miR-200b in various cell lines. UV-detector; the partial
denaturing temperature, 55.6°C; U, peak for the unmethylated PCR
products; M, peak for the methylated PCR products; B, peripheral blood
DNA; MB, M.sssI-methylated blood DNA. Figure S9. DHPLC chromatogram
of methylated and unmethylated miR-193b in various cell lines
Fluorescence-detector; the partial denaturing temperature, 56.5°C; U,
peak for the unmethylated PCR products; M, peak for the methylated
PCR products; B, peripheral blood DNA; MB, M.sssI-methylated blood DNA.
Figure S10. DHPLC chromatogram of methylated and unmethylated
miR-203 in various cell lines. UV-detector; the partial denaturing
temperature, 57.7°C; U, peak for the unmethylated PCR products; M, peak
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methylated blood DNA. Figure S11. Distribution of miR methylation in
various gastric mucosa samples with and without H. pylori infection. Each
line represents methylation status of one miR gene and each column
represents one sample. The proportion of methylated allele is displayed
step-wisely: negative (white square), positive and <30% (light gray square),
or 30%–60% (deep gray square) or >60% (black square). Not informative
sample is marked as “ND”. The case with or without H. pylori-specific 23 S
rDNA was labeled with letter “p” (light green) and “n” (blue square).
Figure S12. Comparison of levels of 7 mature miRNAs by quantitative RT-
PCR in 20 pairs of fresh gastric carcinoma (GC) and the corresponding
surgical margin (SM) tissue samples. The relative miRNA levels of the
paired GC and SM samples from the same patient were linked by a line.
Table S1. Classification of 129 CpG island-related human miR genes from
miRBase (Release 14.0). Table S2. Summary of reported data on the
inverse methylation-expression relationship for 9 representative miR CpG
islands analyzed in the present study. Table S3. Primer sequences,
amplicons, and PCR/DHPLC annealing/ denaturing temperatures used in
the detection of the methylation status of 9 miR CpG islands. Table S4.
Methylation status of 7 miR CpG islands in the paired gastric carcinoma
(GC) and corresponding surgical margin (SM) samples from a total of 112
GC patients. Table S5. miRNA polyA primer for quantitative RT-PCR assays.
Table S6. Comparison of the methylation status in 7 miR genes from the
surgical margin (SM) samples of 112 GC patients with various
clinicopathological characteristics. Table S7. Univariate analysis of the
relationship between overall survival of GC patients and miR-9-1
methylation or other clinicopathological characteristics.
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